
In 2018, wound dressing purchase from medical institutions is estimated to have reached approximately US$*** million, which is the sum of reimbursement products, US$*** million and non-reimbursement products US$*** million. The market size grew ***% over three years from about US$*** million in 2016. In addition, the there is an increase of ***% YoY in 2017, purchase price of In addition, the company increased ***% YoY and total purchase price of US$*** million. Therefore, reimbursement expansion of national health insurance has contributed the rapid growth of this market.
In 2018, among National Health Insurance wound dressing claim amount of US$*** million from medical institutions, it is segmented as following: foam dressing US$*** million (***%), NPWT US$*** million (***%), hydrocolloid US$*** million (***%), film US$*** million (***%), synthetic gauze US$*** million, alginate/hydrofiber US$*** million.
There are total *** of advanced wound dressing distributors who are manufacturers and/or importers who have listed approximately *** types of products (based on the product code listed on the ``Therapeutic products Reimbursement / Non-Reimbursement List and Maximum Cap Price Table''. Among these, the top *** companies market share is approximately ***% of the total market and about *** companies supplied rest of ***%. Based on the upper limit of health insurance treatment products of wound dressing market purchase price and market share of top *** companies(non-reimbursement products are based on medical institution purchase price), it is composed of following: Molnycke US$*** million, Smith&Nephew US$*** million, Mundi Pharma US$*** million, US$*** million Juthis, and US$*** million Ildong.
In 2018, total cost of wound dressing by medical department are composed of following: US$*** million of surgery (***%), US$*** million of internal medicine (***%), US$*** million of orthopedics (***%) followed by US$*** million of plastic surgery (***%)
In 2018, total cost of wound dressing by end users are composed of following: US$*** of tertiary hospital, and it has the largest segment of ***% among wound dressing Claim Amount , followed by US$*** million of general hospital (***%) and US$*** million of hospital (***%).
For the next five years, with at least ***% annual growth rate, the medical institution purchase price of wound dressing market in Korea is expected to grow US$ *** million by 2023. The sustained growth of the wound dressings market is due to all the major factors that have a significant impact on the demand for wound care. Rapid aging, a steady increase in the number of surgeries, an increase in the wound care demand, an increase in the diabetic population, an increase in pressure sores, burns, and cosmetic surgery will drive the continuous growth of this market in the future.
Health insurance in Korea is both play a role as an opportunity and a threat in the wound dressing market in Korea. In the last two decades, health insurance has played a leading role in growing the wound dressing market by continuously increasing the reimbursement coverage. In the future, health insurance will be the biggest variable for the growth of wound dressings. There still is a need for products implemented with new technology that provide convenience and clinical benefit to users and patients. The employer and the patient are willing to pay extra if the product is valuable, even if it is not necessarily covered by the insurance. However, the wound dressing classification system of health insurance currently makes it very difficult for new technology products to be listed in new categories and approved for new prices. For these products, demonstrating cost-effectiveness or quality of life based on clinical evidence will be the biggest barrier to new products.
êµë‚´ ì˜ë£Œê¸°ê´€ì€ 2018ë…„ 약 ***ì›ì˜ ì°½ìƒí”¼ë³µìž¬ë¥¼ 구입한 것으로 추산ëœë‹¤. ì´ ì¤‘ 급여 ì œí’ˆì— ëŒ€í•œ êµ¬ìž…ê¸ˆì•¡ì´ ì•½ ***ì–µ ì›, 비급여 ì œí’ˆì— ëŒ€í•œ 구입 ê¸ˆì•¡ì´ ì•½ ***ì–µ ì›ì— ì´ë¥¸ 것으로 ì¶”ì •ëœë‹¤. ì´ ê·œëª¨ì˜ ì‹œìž¥ì€ 2016ë…„ 약 ***ì–µ ì›ì—서 3ë…„ê°„ ***% 급성장한 것ì´ë‹¤. ë˜í•œ, ì „ë…„ëŒ€ë¹„ 2017ë…„ 구입금액 약 ***ì–µ ì›ì—서 ***% ì¦ê°€í•œ 것ì´ë‹¤. êµë¯¼ê±´ê°•ë³´í—˜ì˜ ê¸‰ì—¬ 확대가 ì´ ì‹œìž¥ ë¹ ë¥¸ ì„±ìž¥ì˜ ë°‘ë°”íƒ•ì´ ë˜ì—ˆë‹¤.
í¼ë“œë ˆì‹±ì´ 가장 í° ë¹„ì¤‘ì„ ì°¨ì§€í•˜ì˜€ë‹¤. 2018ë…„ 중 ì˜ë£Œê¸°ê´€ ê¸‰ì—¬ì œí’ˆ 구입량 ***ì–µ ì› ì¤‘ì—서 í¼ë“œë ˆì‹±ì´ 약 ***ì–µ ì› (***%)ì„ ì°¨ì§€í•˜ì˜€ë‹¤. ì´ì–´ì„œ ì§„ê³µìŒì••ì°½ìƒì²˜ì¹˜ìš© ë“œë ˆì‹± 약 ***ì–µ ì› (***%), 하ì´ë“œë¡œì½œë¡œì´ë“œ 약 ***ì–µ ì› (***%), í•„ë¦„ë“œë ˆì‹± 약 ***ì–µ ì› (***%), í•©ì„±ê±°ì¦ˆë“œë ˆì‹± 약 ***ì–µ ì›(***%), 알지네ì´íЏ/하ì´ë“œë¡œíŒŒì´ë²„ 약 ***ì–µ ì› (***%) 순으로 나머지 ì‹œìž¥ì„ êµ¬ì„±í•˜ì˜€ë‹¤.
2018ë…„ êµë‚´ì—는 약 ***ì—¬ ì œì¡°ì‚¬/수입사가 ì´ ì•½ *** ì¢…ì˜ ì œí’ˆ (「치료재료 급여ã†ë¹„급여 ëª©ë¡ ë° ê¸‰ì—¬ìƒí•œê¸ˆì•¡í‘œã€ì— ë“±ìž¬ëœ ì œí’ˆ 코드 기준)ì— ê±´ê°•ë³´í—˜ì— ë“±ìž¬ë˜ì–´ 있었다. ì´ ì¤‘ 공급량 ìƒìœ„ ***ê°œì‚¬ì˜ í•©ê³„ 시장ì ìœ ìœ¨ì´ ì‹œìž¥ ì „ì²´ì˜ ì•½ ***%를 ì°¨ì§€í•˜ì˜€ê³ , 나머지 약 ***ê°œ 공급사가 ì‹œìž¥ì˜ ë‚˜ë¨¸ì§€ ***%를 공급한 것으로 ì•Œë ¤ì§„ë‹¤. ì°½ìƒí”¼ë³µìž¬ 시장ì—서 ìƒìœ„ ***개사가 공급한 구입금액과 시장ì ìœ ìœ¨ì€ ê±´ê°•ë³´í—˜ 치료재료ìƒí•œê¸ˆì•¡ 기준 (ë¹„ê¸‰ì—¬ì œí’ˆ ê¸°ì¤€ì€ ì˜ë£Œê¸°ê´€ 구입가)으로 멘리케헬스케어코리아 ***ì–µ ì› (***%), 스미스앤드네퓨 ***ì–µ ì› (***%), 한êµë¨¼ë””파마 ***ì–µ ì› (***%), 쥬디스코í¼ë ˆì´ì…˜ ***ì–µ ì› (***%), ì¼ë™ì µÓ•½ ***ì–µ ì› (***%) 로 ì¶”ì •ëœë‹¤.
2018ë…„ ì˜ë£Œê¸°ê´€ì—서 ì°½ìƒí”¼ë³µìž¬ ì‚¬ìš©ëŸ‰ì„ ì§„ë£Œê³¼ë³„ë¡œ 살펴보면, ì²êµ¬ê¸ˆì•¡ 기준으로 ì¼ë°˜ì™¸ê³¼ ***ì–µ ì› (***%), ë‚´ê³¼ ***ì–µ ì› (***%), ì •í˜•ì™¸ê³¼ ***ì–µ ì› (***%), 성형외과 ***ì–µ ì› (***%) 순으로 ì²êµ¬ê¸ˆì•¡ì´ 높았다.
2018ë…„ ì°½ìƒí”¼ë³µìž¬ 급여 ì²êµ¬ê¸ˆì•¡ì„ 기관 ìœ í˜•ë³„ë¡œ ë³´ë©´, ìƒê¸‰ì¢…합병ì›ì´ 구입금액 기준 약 ***ì–µ ì›ìœ¼ë¡œ ì „ì²´ ì²êµ¬ê¸ˆì•¡ 중 가장 í° ë¹„ìœ¨ì¸ ***%를 차지하였다. ì´ì–´ì„œ ì¢…í•©ë³‘ì› ***ì–µ ì› (***%), ë³‘ì› ***ì–µ ì› (***%) 순ì´ì—ˆë‹¤.
향후 ì˜ë£Œê¸°ê´€ì˜ ì°½ìƒí”¼ë³µìž¬ êµ¬ìž…ëŸ‰ì€ í–¥í›„ 5ë…„ê°„ ì—°í‰ê· 최소 ***% 로 성장하여, 2023ë…„ì—는 약 ***ì–µ ì›ì— ì´ë¥¼ 것으로 예ìƒëœë‹¤. ì´ë ‡ê²Œ ì°½ìƒí”¼ë³µìž¬ ì‹œìž¥ì˜ ì§€ì†ì ì„±ìž¥ì€ ì°½ìƒì²˜ì¹˜ ìˆ˜ìš”ì— ì¤‘ìš”í•œ ì˜í–¥ì„ 주는 주요 ìš”ì¸ì´ ëª¨ë‘ ì¦ê°€í•˜ê³ 있기 때문ì´ë‹¤. 급격한 ì¸êµ¬ ê³ ë ¹í™”, ìˆ˜ìˆ ê±´ìˆ˜ì˜ ê¾¸ì¤€í•œ ì¦ê°€, ì°½ìƒì²˜ì¹˜ ìˆ˜ìš”ì˜ ì¦ê°€, 당뇨ì¸êµ¬ ì¦ê°€, ìš•ì°½ì˜ ì¦ê°€, í™”ìƒ, 미용성형 ë“±ì´ ë¯¸ëž˜ì— ì´ ì‹œìž¥ì˜ ê¾¸ì¤€í•œ ì„±ìž¥ì„ ê²¬ì¸í• 것ì´ë‹¤.
êµë‚´ ì°½ìƒí”¼ë³µìž¬ 시장ì—서 ê±´ê°•ë³´í—˜ì€ ê¸°íšŒì´ìž ìœ„í˜‘ì˜ ìš”ì†Œì´ë‹¤. 최근 20여년간 ê±´ê°•ë³´í—˜ì€ ê¸‰ì—¬ë²”ìœ„ë¥¼ 꾸준히 ëŠ˜ë ¤ ì°½ìƒí”¼ë³µìž¬ ì‹œìž¥ì„ ì„±ìž¥ì‹œí‚¤ëŠ” ì¼ë“± ê³µì‹ ì˜ ì—í• ì„ í•´ì™”ë‹¤. 향후ì—ë„ ê±´ê°•ë³´í—˜ì´ ì°½ìƒí”¼ë³µìž¬ì˜ ì„±ìž¥ì— ê°€ìž¥ í° ë³€ìˆ˜ê°€ ë 것ì´ë‹¤. 사용ìžì™€ 환ìžì—게 편리성과 ìž„ìƒì 효과를 ì œê³µí•˜ëŠ”, 새로운 ê¸°ìˆ ì˜ ì œí’ˆì— ëŒ€í•œ 수요는 존재한다. 사용ìžì™€ 환ìžëŠ” 반드시 ê±´ê°•ë³´í—˜ì—서 급여ë˜ì§€ 않아ë„, 가치가 있는 ì œí’ˆì´ë¼ë©´ ì¶”ê°€ì˜ ë¹„ìš©ì„ ì§€ë¶ˆí• ì˜ì‚¬ê°€ 있다. 그러나, 현재 ê±´ê°•ë³´í—˜ì˜ ì°½ìƒí”¼ë³µìž¬ 분류 체계는 새로운 ê¸°ìˆ ì˜ ì œí’ˆì´ ìƒˆë¡œìš´ 분류와 새로운 ë³´í—˜ê°€ê²©ì— ë“±ìž¬í•˜ëŠ” ê²ƒì„ ë§¤ìš° ì–´ë µê²Œ í•˜ê³ ìžˆë‹¤. ìž„ìƒê·¼ê±°ë¥¼ 바탕으로 한 비용효과성 ë˜ëŠ” ì‚¶ì˜ ì§ˆ í–¥ìƒ íš¨ê³¼ ìž…ì¦ì´ 새로운 ì œí’ˆì´ ë„˜ì–´ì•¼ í• ê°€ìž¥ í° ìž¥ë²½ì´ ë 것ì´ë‹¤.
Ìý
Ìý
Ìý
*If Applicable.
